Maze Therapeutics (NASDAQ:MAZE) shares were trading largely flat following a $140M initial public offering. Shares of the kidney disease drug developer opened at $16 per share after being priced at ...
Find Complicated Maze stock video, 4K footage, and other HD footage from iStock. Get higher quality Complicated Maze content, for less—All of our 4K video clips are the same price as HD. Video Back ...
Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...